Novo Nordisk's Cagri-Sema Evergreening The Franchise Part I Novo Nordisk, the leader in weight loss market, is going after tolerability instead of efficacy with this combination drug targeting GLP-1 and amylin
Given these factors, we strongly urge our readers to approach Semigline with caution
"Your firm became aware of the event on June 20, 2024, and FDA received the MDR, 1220908202500947, for the corresponding incident on March 10, 2025, which is beyond the 30calendar day timeframe." FDA issued warning letters to three drug manufacturers, including the Canadian over-the-counter drugmaker Sante Manufacturing, for failing to adhere to CGMP requirements
At 5mg/mL, a 0.5mg dose is 10 units, not 50
Every 6 to 12 months once stable: After your thyroid levels have stabilized and any levothyroxine dose adjustments have been made, you can return to testing every 6 to 12 months